[Acromegaly]
- PMID: 19004612
- DOI: 10.1016/j.lpm.2008.09.016
[Acromegaly]
Abstract
Acromegaly is a rare disease usually caused by growth hormone (GH) hypersecretion, due to a pituitary adenoma; in very rare cases, acromegaly is due to ectopic secretion of GHRH, responsible for pituitary hyperplasia. Owing to its insidious onset, acromegaly is often diagnosed late (4 to > 10 years after onset), at an average age of about 40 years, in front of an acquired, slowly progressing disfigurement mainly involving the face and extremities. Acromegaly has also rheumatologic, cardiovascular, respiratory and metabolic consequences which determine its prognosis. The diagnosis is based on an increased serum GH concentration unsuppressed following an oral glucose load (oral glucose tolerance test -OGTT-) and an increased insulin-like growth factor-I (IGF-I); according to a 2000 Consensus statement, if the basal serum GH is above 0,4microg/L (1.2mIU/L) and/or if the IGF-I is elevated, an OGTT must be performed. If the lowest GH value (nadir) during OGTT remains above 1microg/L (3mIU/L), acromegaly is confirmed. With the generalized use of very sensitive assays nowadays, it has recently been considered that this cutoff should be decreased to 0,3microg/L (0.9mIU/L). Treatment is aimed at correcting (or preventing) tumor compression by excising the culprit lesion, and at reducing GH and IGF-I levels to normal values (or at least to a "safe" GH level of < 2microg/L or < 6mIU/L). A stepwise therapeutic strategy is used: transsphenoidal surgery is often the first-line treatment; when surgery fails to correct GH/IGF-I hypersecretion, medical treatment with somatostatin analogs and/or radiotherapy can be used, somatostatin analogs being generally preferred; the GH antagonist (pegvisomant) is used in patients that are resistant or intolerant to somatostatin analogs. Prognosis of acromegaly has improved in the recent years: adequate hormonal disease control is achieved in most cases, allowing life expectancy similar to that of the general population.
Similar articles
-
Acromegaly.Orphanet J Rare Dis. 2008 Jun 25;3:17. doi: 10.1186/1750-1172-3-17. Orphanet J Rare Dis. 2008. PMID: 18578866 Free PMC article. Review.
-
Acromegaly.Handb Clin Neurol. 2014;124:197-219. doi: 10.1016/B978-0-444-59602-4.00014-9. Handb Clin Neurol. 2014. PMID: 25248589 Review.
-
Pituitary tumours: acromegaly.Best Pract Res Clin Endocrinol Metab. 2009 Oct;23(5):555-74. doi: 10.1016/j.beem.2009.05.010. Best Pract Res Clin Endocrinol Metab. 2009. PMID: 19945023 Review.
-
Acromegaly.Pituitary. 2006;9(4):297-303. doi: 10.1007/s11102-006-0409-4. Pituitary. 2006. PMID: 17077948 Review.
-
Hormonal diagnosis of GH hypersecretory states.J Endocrinol Invest. 2003;26(10 Suppl):27-35. J Endocrinol Invest. 2003. PMID: 15497657 Review.
Cited by
-
Prevalence and outcome of comorbidities associated with acromegaly.Acta Neurochir (Wien). 2021 Nov;163(11):3171-3180. doi: 10.1007/s00701-021-04846-8. Epub 2021 Apr 15. Acta Neurochir (Wien). 2021. PMID: 33856552
-
Daily life reflections of acromegaly guidelines.J Endocrinol Invest. 2017 Mar;40(3):323-330. doi: 10.1007/s40618-016-0567-9. Epub 2016 Oct 20. J Endocrinol Invest. 2017. PMID: 27766549
-
Acromegaly without acral changes: A rare presentation.Indian J Endocrinol Metab. 2012 May;16(3):457-9. doi: 10.4103/2230-8210.95713. Indian J Endocrinol Metab. 2012. PMID: 22629521 Free PMC article.
-
Familial isolated pituitary adenomas: an emerging clinical entity.J Endocrinol Invest. 2012 Dec;35(11):1003-14. doi: 10.1007/BF03346742. J Endocrinol Invest. 2012. PMID: 23310926 Review.
-
[Destructive arthropathy of the shoulder during an acromegaly].Pan Afr Med J. 2011;10:12. doi: 10.4314/pamj.v10i0.72220. Epub 2011 Oct 1. Pan Afr Med J. 2011. PMID: 22187594 Free PMC article. French.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources